Literature DB >> 30457485

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.

Mizuki Nishino1, Hiroto Hatabu1, F Stephen Hodi1.   

Abstract

Cancer immunotherapy using immune-checkpoint inhibitors has emerged as an effective treatment option for a variety of advanced cancers in the past decade. Because of the distinct mechanisms of immunotherapy that activate the host immunity to treat cancers, unconventional immune-related phenomena are encountered in terms of tumor response and progression, as well as drug toxicity. Imaging plays an important role in objectively characterizing immune-related tumor responses and progression and in detecting and monitoring immune-related adverse events. Moreover, emerging data suggest a promise for molecular imaging that can visualize the specific target molecules involved in immune-checkpoint pathways. In this article, the background and current status of cancer immunotherapy are summarized, and the current methods for imaging evaluations of immune-related responses and toxicities are reviewed along with their limitations and pitfalls. Emerging approaches with molecular imaging are also discussed as a future direction to address unmet needs. © RSNA, 2018.

Entities:  

Mesh:

Year:  2018        PMID: 30457485      PMCID: PMC6312436          DOI: 10.1148/radiol.2018181349

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  84 in total

1.  Pseudoprogression and Immune-Related Response in Solid Tumors.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

2.  CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

Authors:  Mizuki Nishino; Mengye Guo; David M Jackman; Pamela J DiPiro; Jeffrey T Yap; Tak K Ho; Hiroto Hatabu; Pasi A Jänne; Annick D Van den Abbeele; Bruce E Johnson
Journal:  Acad Radiol       Date:  2010-10-30       Impact factor: 3.173

3.  Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Authors:  Mizuki Nishino; Lynette M Sholl; Mark M Awad; Hiroto Hatabu; Philippe Armand; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2018-04-05       Impact factor: 11.151

Review 4.  Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.

Authors:  Mizuki Nishino; Sree H Tirumani; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Eur J Radiol       Date:  2015-03-23       Impact factor: 3.528

5.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 6.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Authors:  Lesley Seymour; Jan Bogaerts; Andrea Perrone; Robert Ford; Lawrence H Schwartz; Sumithra Mandrekar; Nancy U Lin; Saskia Litière; Janet Dancey; Alice Chen; F Stephen Hodi; Patrick Therasse; Otto S Hoekstra; Lalitha K Shankar; Jedd D Wolchok; Marcus Ballinger; Caroline Caramella; Elisabeth G E de Vries
Journal:  Lancet Oncol       Date:  2017-03-02       Impact factor: 41.316

7.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

Authors:  Daniel S Chen; Bryan A Irving; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531

10.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Authors:  Romualdo Barroso-Sousa; William T Barry; Ana C Garrido-Castro; F Stephen Hodi; Le Min; Ian E Krop; Sara M Tolaney
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

View more
  39 in total

1.  Low-Dose Chest CT for the Diagnosis of COVID-19—A Systematic, Prospective Comparison With PCR

Authors:  Maximilian Schulze-Hagen; Christian Hübel; Michael Meier-Schroers; Can Yüksel; Anton Sander; Marwin Sähn; Michael Kleines; Peter Isfort; Christian Cornelissen; Sebastian Lemmen; Nikolaus Marx; Michael Dreher; Jörg Brokmann; Andreas Kopp; Christiane Kuhl
Journal:  Dtsch Arztebl Int       Date:  2020-06-01       Impact factor: 5.594

2.  Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging.

Authors:  Nemi Gandy; Mubarik A Arshad; Kathryn L Wallitt; Suraiya Dubash; Sameer Khan; Tara D Barwick
Journal:  Br J Radiol       Date:  2020-02-27       Impact factor: 3.039

Review 3.  Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.

Authors:  Ali Pourvaziri; Anushri Parakh; Pierpaolo Biondetti; Dushyant Sahani; Avinash Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-09

4.  Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.

Authors:  Hyesun Park; Hiroto Hatabu; Biagio Ricciuti; Safiya J Aijazi; Mark M Awad; Mizuki Nishino
Journal:  Eur J Radiol       Date:  2020-09-10       Impact factor: 3.528

Review 5.  Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.

Authors:  Minghao Wu; Yanyan Zhang; Yuwei Zhang; Ying Liu; Mingjie Wu; Zhaoxiang Ye
Journal:  Radiol Imaging Cancer       Date:  2019-11-29

6.  Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis.

Authors:  Hyo Jung Park; Kyung Won Kim; Junhee Pyo; Chong Hyun Suh; Shinkyo Yoon; Hiroto Hatabu; Mizuki Nishino
Journal:  Radiology       Date:  2020-08-04       Impact factor: 11.105

Review 7.  Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Authors:  Hyesun Park; Lynette M Sholl; Hiroto Hatabu; Mark M Awad; Mizuki Nishino
Journal:  Radiology       Date:  2019-08-06       Impact factor: 11.105

8.  Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis.

Authors:  Jeffrey P Guenette; Raymond Y Huang; Pyeong Hwa Kim; Chong Hyun Suh; Ho Sung Kim; Kyung Won Kim; Dong Yeong Kim; Ayal A Aizer; Rifaquat Rahman
Journal:  Eur Radiol       Date:  2020-11-25       Impact factor: 5.315

Review 9.  Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.

Authors:  Caroline Robert; Aurelien Marabelle; Hugo Herrscher; Caroline Caramella; Pascal Rouby; Karim Fizazi; Benjamin Besse
Journal:  Nat Rev Clin Oncol       Date:  2020-07-07       Impact factor: 66.675

10.  Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

Authors:  Mizuki Nishino; Fangxin Hong; Biagio Ricciuti; Hiroto Hatabu; Mark M Awad
Journal:  JCO Precis Oncol       Date:  2021-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.